822 A1A NORTH, PONTE VEDRA, FL
Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of Its Orphan Thrombo-Inflammatory Therapeutics
Cadrenal Therapeutics Approves Amendment to 2022 Equity Incentive Plan
Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
Annual Report to Security Holders
Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
Chief Medical Officer Departure - James J. Ferguson Resigns
CMO Departure - James J. Ferguson III Resigns from Cadrenal Therapeutics
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Notice of Exempt Offering of Securities
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement